Deprescribing a long-term antipsychotic for behavioural and psychological symptoms of dementia
Patients taking an antipsychotic long term (for 12 weeks or longer) for a behavioural and psychological symptom of dementia (BPSD) can usually stop the antipsychotic without their symptom worsening. Rarely, patients will experience a worsening of symptoms if their symptoms were initially severe (eg psychotic features, violent aggression)—seek expert (eg psychiatrist, neurologist, geriatrician) advice before deprescribing. Patients whose symptoms were not initially severe can become less agitated when the antipsychotic is stopped.
If an antipsychotic has been used to treat behavioural and psychological symptoms of dementia for 12 weeks or longer, begin deprescribing if:
- any of the criteria for stopping an antipsychotic set out in Follow-up and duration of antipsychotic therapy for agitation, aggression or psychosis of dementia are met (eg target symptoms have not improved)
- it is used for a behavioural or psychological symptom of dementia other than agitation, aggression or psychosis (eg wandering)
- target symptoms appear stable.
Simultaneously engage in shared decision making with the patient or their substitute decision-maker and, if they consent , their family, carers or significant others. Discuss:
- the role of antipsychotic therapy in achieving the patient’s treatment goals
- the deprescribing process (see below), including that it is a trial and the antipsychotic can be restarted if required
- any fears and concerns the patient or their substitute decision-maker, family, carers or significant others have about deprescribing
- the benefits and harms of deprescribing. Potential benefits include improvements in cognition and behaviour, and a reduced risk of mortality, falls, fractures, cerebrovascular events and other adverse effects. Potential harms include worsening of behavioural symptoms and withdrawal effects if the antipsychotic is stopped too abruptly; however, these responses are uncommon.
On the basis of these discussions, collaboratively develop a plan1 that sets out the approach to monitoring, dosage adjustment, optimising nonpharmacological management (which is especially important if symptoms re-emerge) and indicators for restarting an antipsychotic. Involve relevant healthcare professionals in the plan’s development.